We wonder if the cisplatin-based chemotherapy may have promoted the genesis of the second ROS1+ NSCLC given that cisplatin induces DNA strand breaks and the gCHEK2m reduces the corrective response to DNA breaks. Here, ROS1 is linked to non-small cell lung carcinoma.